Original Publication Date: 1 January, 2014
Publication / Source: Lung Cancer Management
Authors: Andrea Botticelli, Federica Mazzuca, Chiara Maddalena & Paolo Marchetti
Atypical bronchopulmonary carcinoid is a rare disease with poor prognosis. The low number of patients and their dispersion in different centers makes it difficult to draw clinical trials. The right treatment is still controversial. This study reports the clinical case of a patient with bronchopulmonary carcinoid, who showed stable disease with everolimus (an mTOR inhibitor) plus somatostatin analog after the failure of two lines of chemotherapy plus somatostatin analog.